The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. / Esteves, Sandro C; Alviggi, Carlo; Humaidan, Peter; Fischer, Robert; Andersen, Claus Y; Conforti, Alessandro; Bühler, Klaus; Sunkara, Sesh K; Polyzos, Nikolaos P; Galliano, Daniela; Grynberg, Michael; Yarali, Hakan; Özbek, Irem Y; Roque, Matheus; Vuong, Lan N; Banker, Manish; Rienzi, Laura; Vaiarelli, Alberto; Cimadomo, Danilo; Ubaldi, Filippo M.

I: Frontiers in Endocrinology, Bind 10, 814, 2019.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Esteves, SC, Alviggi, C, Humaidan, P, Fischer, R, Andersen, CY, Conforti, A, Bühler, K, Sunkara, SK, Polyzos, NP, Galliano, D, Grynberg, M, Yarali, H, Özbek, IY, Roque, M, Vuong, LN, Banker, M, Rienzi, L, Vaiarelli, A, Cimadomo, D & Ubaldi, FM 2019, 'The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists', Frontiers in Endocrinology, bind 10, 814. https://doi.org/10.3389/fendo.2019.00814

APA

Esteves, S. C., Alviggi, C., Humaidan, P., Fischer, R., Andersen, C. Y., Conforti, A., Bühler, K., Sunkara, S. K., Polyzos, N. P., Galliano, D., Grynberg, M., Yarali, H., Özbek, I. Y., Roque, M., Vuong, L. N., Banker, M., Rienzi, L., Vaiarelli, A., Cimadomo, D., & Ubaldi, F. M. (2019). The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. Frontiers in Endocrinology, 10, [814]. https://doi.org/10.3389/fendo.2019.00814

CBE

Esteves SC, Alviggi C, Humaidan P, Fischer R, Andersen CY, Conforti A, Bühler K, Sunkara SK, Polyzos NP, Galliano D, Grynberg M, Yarali H, Özbek IY, Roque M, Vuong LN, Banker M, Rienzi L, Vaiarelli A, Cimadomo D, Ubaldi FM. 2019. The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. Frontiers in Endocrinology. 10:Article 814. https://doi.org/10.3389/fendo.2019.00814

MLA

Vancouver

Esteves SC, Alviggi C, Humaidan P, Fischer R, Andersen CY, Conforti A o.a. The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. Frontiers in Endocrinology. 2019;10. 814. https://doi.org/10.3389/fendo.2019.00814

Author

Esteves, Sandro C ; Alviggi, Carlo ; Humaidan, Peter ; Fischer, Robert ; Andersen, Claus Y ; Conforti, Alessandro ; Bühler, Klaus ; Sunkara, Sesh K ; Polyzos, Nikolaos P ; Galliano, Daniela ; Grynberg, Michael ; Yarali, Hakan ; Özbek, Irem Y ; Roque, Matheus ; Vuong, Lan N ; Banker, Manish ; Rienzi, Laura ; Vaiarelli, Alberto ; Cimadomo, Danilo ; Ubaldi, Filippo M. / The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists. I: Frontiers in Endocrinology. 2019 ; Bind 10.

Bibtex

@article{8f2a3260fc054122bfdd9753aadc1565,
title = "The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists",
abstract = "This article represents a viewpoint on the POSEIDON criteria by a group of clinicians and embryologists. Its primary objective is to contextualize the Poseidon criteria and their metric of success for the relevant Frontiers Research Topic {"}POSEIDON's Stratification of Low Prognosis Patients in ART: The WHY, the WHAT, and the HOW{"}. {"}Low prognosis{"} relates with reduced oocyte number, which can be associated with low or sometimes a normal ovarian reserve and is aggravated by advanced female age. These aspects will ultimately affect the number of embryos generated and consequently, the cumulative live birth rate. The novel system relies on female age, ovarian reserve markers, ovarian sensitivity to exogenous gonadotropin, and the number of oocytes retrieved, which will both identify the patients with low prognosis and stratify such patients into one of four groups of women with {"}expected{"} or {"}unexpected{"} impaired ovarian response to exogenous gonadotropin stimulation. Furthermore, the POSEIDON group introduced a new measure of clinical success in ART, namely, the ability to retrieve the number of oocytes needed to obtain at least one euploid blastocyst for transfer in each patient. Using the POSEIDON criteria, the clinician can firstly identify and classify patients who have low prognosis in ART, and secondly, aim at designing an individualized treatment plan to maximize the chances of achieving the POSEIDON measure of success in each of the four low prognosis groups. The novel POSEIDON classification system is anticipated to improve counseling and management of low prognosis patients undergoing ART, with an expected positive effect on reproductive success and a reduction in the time to live birth.",
keywords = "ANTIMULLERIAN HORMONE, ART calculator, ASSISTED REPRODUCTIVE TECHNOLOGY, CONTROLLED OVARIAN STIMULATION, FERTILITY CARE, FERTILIZATION/INTRACYTOPLASMIC SPERM INJECTION, IN-VITRO FERTILIZATION, LIVE BIRTH-RATES, LONGITUDINAL COHORT, LOW PROGNOSIS PATIENTS, POSEIDON criteria, SINGLE-EMBRYO-TRANSFER, assisted reproductive technology, blastocyst, low prognosis, oocyte, ovarian stimulation, poor ovarian response",
author = "Esteves, {Sandro C} and Carlo Alviggi and Peter Humaidan and Robert Fischer and Andersen, {Claus Y} and Alessandro Conforti and Klaus B{\"u}hler and Sunkara, {Sesh K} and Polyzos, {Nikolaos P} and Daniela Galliano and Michael Grynberg and Hakan Yarali and {\"O}zbek, {Irem Y} and Matheus Roque and Vuong, {Lan N} and Manish Banker and Laura Rienzi and Alberto Vaiarelli and Danilo Cimadomo and Ubaldi, {Filippo M}",
note = "Copyright {\textcopyright} 2019 Esteves, Alviggi, Humaidan, Fischer, Andersen, Conforti, B{\"u}hler, Sunkara, Polyzos, Galliano, Grynberg, Yarali, {\"O}zbek, Roque, Vuong, Banker, Rienzi, Vaiarelli, Cimadomo and Ubaldi.",
year = "2019",
doi = "10.3389/fendo.2019.00814",
language = "English",
volume = "10",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S.A",

}

RIS

TY - JOUR

T1 - The POSEIDON Criteria and Its Measure of Success Through the Eyes of Clinicians and Embryologists

AU - Esteves, Sandro C

AU - Alviggi, Carlo

AU - Humaidan, Peter

AU - Fischer, Robert

AU - Andersen, Claus Y

AU - Conforti, Alessandro

AU - Bühler, Klaus

AU - Sunkara, Sesh K

AU - Polyzos, Nikolaos P

AU - Galliano, Daniela

AU - Grynberg, Michael

AU - Yarali, Hakan

AU - Özbek, Irem Y

AU - Roque, Matheus

AU - Vuong, Lan N

AU - Banker, Manish

AU - Rienzi, Laura

AU - Vaiarelli, Alberto

AU - Cimadomo, Danilo

AU - Ubaldi, Filippo M

N1 - Copyright © 2019 Esteves, Alviggi, Humaidan, Fischer, Andersen, Conforti, Bühler, Sunkara, Polyzos, Galliano, Grynberg, Yarali, Özbek, Roque, Vuong, Banker, Rienzi, Vaiarelli, Cimadomo and Ubaldi.

PY - 2019

Y1 - 2019

N2 - This article represents a viewpoint on the POSEIDON criteria by a group of clinicians and embryologists. Its primary objective is to contextualize the Poseidon criteria and their metric of success for the relevant Frontiers Research Topic "POSEIDON's Stratification of Low Prognosis Patients in ART: The WHY, the WHAT, and the HOW". "Low prognosis" relates with reduced oocyte number, which can be associated with low or sometimes a normal ovarian reserve and is aggravated by advanced female age. These aspects will ultimately affect the number of embryos generated and consequently, the cumulative live birth rate. The novel system relies on female age, ovarian reserve markers, ovarian sensitivity to exogenous gonadotropin, and the number of oocytes retrieved, which will both identify the patients with low prognosis and stratify such patients into one of four groups of women with "expected" or "unexpected" impaired ovarian response to exogenous gonadotropin stimulation. Furthermore, the POSEIDON group introduced a new measure of clinical success in ART, namely, the ability to retrieve the number of oocytes needed to obtain at least one euploid blastocyst for transfer in each patient. Using the POSEIDON criteria, the clinician can firstly identify and classify patients who have low prognosis in ART, and secondly, aim at designing an individualized treatment plan to maximize the chances of achieving the POSEIDON measure of success in each of the four low prognosis groups. The novel POSEIDON classification system is anticipated to improve counseling and management of low prognosis patients undergoing ART, with an expected positive effect on reproductive success and a reduction in the time to live birth.

AB - This article represents a viewpoint on the POSEIDON criteria by a group of clinicians and embryologists. Its primary objective is to contextualize the Poseidon criteria and their metric of success for the relevant Frontiers Research Topic "POSEIDON's Stratification of Low Prognosis Patients in ART: The WHY, the WHAT, and the HOW". "Low prognosis" relates with reduced oocyte number, which can be associated with low or sometimes a normal ovarian reserve and is aggravated by advanced female age. These aspects will ultimately affect the number of embryos generated and consequently, the cumulative live birth rate. The novel system relies on female age, ovarian reserve markers, ovarian sensitivity to exogenous gonadotropin, and the number of oocytes retrieved, which will both identify the patients with low prognosis and stratify such patients into one of four groups of women with "expected" or "unexpected" impaired ovarian response to exogenous gonadotropin stimulation. Furthermore, the POSEIDON group introduced a new measure of clinical success in ART, namely, the ability to retrieve the number of oocytes needed to obtain at least one euploid blastocyst for transfer in each patient. Using the POSEIDON criteria, the clinician can firstly identify and classify patients who have low prognosis in ART, and secondly, aim at designing an individualized treatment plan to maximize the chances of achieving the POSEIDON measure of success in each of the four low prognosis groups. The novel POSEIDON classification system is anticipated to improve counseling and management of low prognosis patients undergoing ART, with an expected positive effect on reproductive success and a reduction in the time to live birth.

KW - ANTIMULLERIAN HORMONE

KW - ART calculator

KW - ASSISTED REPRODUCTIVE TECHNOLOGY

KW - CONTROLLED OVARIAN STIMULATION

KW - FERTILITY CARE

KW - FERTILIZATION/INTRACYTOPLASMIC SPERM INJECTION

KW - IN-VITRO FERTILIZATION

KW - LIVE BIRTH-RATES

KW - LONGITUDINAL COHORT

KW - LOW PROGNOSIS PATIENTS

KW - POSEIDON criteria

KW - SINGLE-EMBRYO-TRANSFER

KW - assisted reproductive technology

KW - blastocyst

KW - low prognosis

KW - oocyte

KW - ovarian stimulation

KW - poor ovarian response

UR - http://www.scopus.com/inward/record.url?scp=85076689200&partnerID=8YFLogxK

U2 - 10.3389/fendo.2019.00814

DO - 10.3389/fendo.2019.00814

M3 - Journal article

C2 - 31824427

VL - 10

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

M1 - 814

ER -